Optimized Alectinib Dose Regimen for Treatment of Patients with ALK-Positive Non-Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence.

2021 
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    5
    References
    2
    Citations
    NaN
    KQI
    []